Bisphosphonates can block the deterioration in implant fixation after withdrawal of intermittent doses of parathyroid hormone

Journal of Bone and Joint Surgery - Series B

Volumn 90, Issue 3, 2008, Pages 400-404

  Johansson, H R ^a,b   Skripitz, R ^a,c   Aspenberg, P ^a,d  

^a IKE   (Sweden)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; SODIUM CHLORIDE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG EFFECT; FRACTURE FIXATION; HISTOLOGY; IMPLANT; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOMECHANICS; BONE DENSITY; BONE RESORPTION; BONE SCREWS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; IMPLANTS, EXPERIMENTAL; MALE; PARATHYROID HORMONE; PROSTHESIS FAILURE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 41149140398     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.90B3.19544     Document Type: Article

References (27)

1. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995;136:3632-8.
2. Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003;278:50259-72.
3. Ejersted C, Andreassen TT, Hauge EM, Melsen F, Oxlund H. Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength and quality in old rats. Bone 1995;17:507-11.
4. Friedl G, Turner RT, Evans GL, Dobnig H. Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism. J Orthop Res 2007;25:1454-64.
5. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999;14:960-8.
6. Skripitz R, Andreassen TT, Aspenberg P. Strong effect of PTH (1-34) on regenerating bone: a time sequence study in rats. Acta Orthop Stand 2000;71:619-24.
7. Skripitz R, Böhling S, Rüther W, Aspenberg P. Stimulation of implant fixation by parathyroid hormone (1-34): a histomorphometric comparison of PMMA cement and stainless steel. J Orthop Res 2005;23:1266-70.
8. Skripitz R, Aspenberg P. Implant fixation enhanced by intermittent treatment with parathyroid hormone. J Bone Joint Surg [Br] 2001;83-B:437-40.
9. Skripitz R, Andreassen TT, Aspenberg P. Parathyroid hormone (1-34) increases for the density of rat cancellous bone in a bone chamber: a dose-response study. J Bone Joint Surg [Br] 2000;82-B:138-41.
10. Skoglund B, Holmertz J, Aspenberg P. Systemic and local ibandronate enhance screw fixation. J Orthop Res 2004;22:1108-13.
11. Gunness-Hey M, Hock JM. Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. J Orthop Res 1989;10:447-52.
12. Skripitz R, Aspenberg P. Parathyroid hormone: a drug for orthopedic surgery? Acta Orthop Scand 2004;75:654-62.
13. Skripitz R, Aspenberg P. Parathyroid hormone (1-34) increases attachment of PMMA cement to bone. J Orthop Sci 2001;6:540-4.
14. Skripitz R, Aspenberg P. Early effect of parathyroid hormone (1-34) on implant fixation. Clin Orthop 2001;392:427-32.
15. Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 2004;89:3332-6.
16. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg [Am] 2004;87-A:1609-18.
17. Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-46.
18. Hodsman AB, Fraher U, Ostbye T, Adachi JD, Steer BM. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 1993;9:1138-48
19. O'Brien CA, Jilka RL, Fu Q, et al. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab 2005;289:784-93.
20. Onyia JE, Helvering LM, Gelbert L, et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysts by DNA microarray. J Cell Biochem 2005;95:403-18.
21. Kwan Tat S, Padrines M, Théoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004;15:49-60.
22. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
23. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-61.
24. Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003;89:180-90.
25. Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82:620-8.
26. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34.
27. Aspenberg P, Van der Vis H. Migration, particles and fluid pressure: a discussion of causes of prosthetic loosening. Clin Orthop 1998;352:75-80.